{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-107873","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.224819+00:00","generated_at":"2026-05-16T22:17:49.156464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protara Therapeutics Q3 net loss $13.3M; cash runway into mid-2027; key trial data readouts on track","bullets":["Net loss of $13.3M ($0.31 per share) vs $11.2M ($0.50 per share) in Q3 2024.","Cash, equivalents and investments $133.6M as of Sept 30, expected to fund operations into mid-2027.","R&D expenses $9.6M, up $1.5M YoY driven by THRIVE-3 startup costs.","ADVANCED-2 interim data from ~25 BCG-Unresponsive NMIBC patients expected 1Q 2026.","STARBORN-1 interim update in pediatric LMs expected 4Q 2025; THRIVE-3 first patient dosing by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-107873","json":"https://secwatch.observer/filing/0001213900-25-107873.json","markdown":"https://secwatch.observer/filing/0001213900-25-107873.md","text":"https://secwatch.observer/filing/0001213900-25-107873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/0001213900-25-107873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea0263183-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:17:49.156464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}